KR20240149422A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20240149422A
KR20240149422A KR1020247030427A KR20247030427A KR20240149422A KR 20240149422 A KR20240149422 A KR 20240149422A KR 1020247030427 A KR1020247030427 A KR 1020247030427A KR 20247030427 A KR20247030427 A KR 20247030427A KR 20240149422 A KR20240149422 A KR 20240149422A
Authority
KR
South Korea
Prior art keywords
lag
protein
derivative
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030427A
Other languages
English (en)
Korean (ko)
Inventor
프레데릭 트리에벨
Original Assignee
이뮤텝 에스.에이.에스.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2201803.0A external-priority patent/GB202201803D0/en
Priority claimed from GBGB2218181.2A external-priority patent/GB202218181D0/en
Application filed by 이뮤텝 에스.에이.에스. filed Critical 이뮤텝 에스.에이.에스.
Publication of KR20240149422A publication Critical patent/KR20240149422A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020247030427A 2022-02-11 2023-02-10 암 치료 Pending KR20240149422A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2201803.0 2022-02-11
GBGB2201803.0A GB202201803D0 (en) 2022-02-11 2022-02-11 Treatment of Cancer
GB2218181.2 2022-12-02
GBGB2218181.2A GB202218181D0 (en) 2022-12-02 2022-12-02 Treatment of cancer
PCT/EP2023/053381 WO2023152335A1 (en) 2022-02-11 2023-02-10 Treatment of cancer

Publications (1)

Publication Number Publication Date
KR20240149422A true KR20240149422A (ko) 2024-10-14

Family

ID=85227021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030427A Pending KR20240149422A (ko) 2022-02-11 2023-02-10 암 치료

Country Status (9)

Country Link
US (1) US20250368714A1 (https=)
EP (1) EP4475955A1 (https=)
JP (1) JP2025505738A (https=)
KR (1) KR20240149422A (https=)
AU (1) AU2023219133A1 (https=)
CA (1) CA3250299A1 (https=)
IL (1) IL314687A (https=)
MX (1) MX2024009818A (https=)
WO (1) WO2023152335A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229157A1 (en) * 2024-05-01 2025-11-06 Immutep S.A.S. Combination therapy using lag-3 protein and anti-pd-1 inhibitor with radiotherapy for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
IL298507A (en) * 2020-05-28 2023-01-01 Immutep Sas Treatment of cancer

Also Published As

Publication number Publication date
EP4475955A1 (en) 2024-12-18
IL314687A (en) 2024-10-01
CA3250299A1 (en) 2023-08-17
MX2024009818A (es) 2024-08-19
AU2023219133A1 (en) 2024-09-05
WO2023152335A1 (en) 2023-08-17
JP2025505738A (ja) 2025-02-28
US20250368714A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
Ma et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
KR101894689B1 (ko) 암의 치료 방법
US10744110B2 (en) Methods of treating lung cancer
Choudhury et al. A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
Wissing et al. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands
Chien et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
AU2016248329A1 (en) Combination treatments with seribantumab
KR20240149422A (ko) 암 치료
Brufsky et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer
CN118804760A (zh) 癌症的治疗
KR20230028321A (ko) 암의 치료
Poole et al. Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer
Carvalho et al. Myelodysplastic syndrome after maintenance treatment with metronomic cyclophosphamide: weighing prolonged stable disease against late toxicity
AU2013203373B2 (en) Methods of treating lung cancer
O'Shaughnessy et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
WO2026039321A1 (en) Methods for treating prostate cancer
Xuhong et al. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial
Vasiliou et al. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011-Focus on first-in-human and phase I trials
Rauthan et al. Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
HK1220110B (en) Methods of treating lung cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000